New pill targets genetic weakness in tough cancers

NCT ID NCT06915753

Recruiting now Disease control Sponsor: Tyra Biosciences, Inc Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new daily pill called TYRA-430 in 100 adults with advanced liver cancer or other solid tumors that have specific genetic changes. The main goals are to find the safest dose and check for side effects. Researchers will also look for signs that the drug shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

TYRA-430 (an oral drug that targets specific genetic changes in cancer cells)

What this could lead to

If successful, this could lead to a new treatment option for people with advanced liver cancer or other solid tumors that have certain genetic changes.

What could go wrong

This is a very early Phase 1 study, so the drug may not work or could have serious side effects. It is only for people with specific genetic changes, so it won't help everyone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS FGF19 GENE AMPLIFICATION FGF19 GENE OVEREXPRESSION FGFR GENE ALTERATIONS FGFR GENE AMPLIFICATION FGFR3 GENE ALTERATION FGFR3 GENE FUSIONS FGFR3 GENE MUTATION FGFR4 GENE FUSIONS FGFR4 GENE MUTATION LOCALLY ADVANCED UNRESECTABLE HEPATOCELLULAR CARCINOMA METASTATIC HEPATOCELLULAR CARCINOMA SOLID TUMOR, ADULT SOLID TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Asan Medical Center
RECRUITING

Seoul, South Korea
Columbia University Irving Medical Center
RECRUITING

New York, New York, 10043, United States
John Hopkins University
RECRUITING

Baltimore, Maryland, 21205, United States
Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48201, United States
Mass General Cancer Center
RECRUITING

Boston, Massachusetts, 02114, United States
National Taiwan University Hospital
RECRUITING

Taipei, Taiwan
Samsung Medical Center
RECRUITING

Seoul, South Korea
Sarah Cannon Research Institute Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Seoul National University Hospital
RECRUITING

Seoul, South Korea
Severance Hospital, Yonsei University Health System
RECRUITING

Seoul, South Korea
Stanford Cancer Institute
RECRUITING

Stanford, California, 94305, United States
Taipei Veterans General Hospital
RECRUITING

Taipei, Taiwan
The University of Kansas Medical Center
RECRUITING

Westwood, Kansas, 66205, United States
UCSF Medical Center at Mount Zion
RECRUITING

San Francisco, California, 94158, United States
USC Norris Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90033, United States
University Health Network Princess Margaret Cancer Center
RECRUITING

Toronto, Ontario, M5G 2C4, Canada